Stem cell transplant or drug combo: which better prevents leukemia return in seniors?
NCT ID NCT06903702
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study tests two strategies to keep acute myeloid leukemia (AML) from coming back in people aged 65 and older who have achieved remission after initial treatment. One group receives a stem cell transplant, while the other continues on a maintenance drug combination of azacitidine and venetoclax. The goal is to see which approach leads to longer relapse-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- azacitidine and venetoclax (drugs); allogeneic stem cell transplant (procedure)
- What this could lead to
- If successful, this trial could identify the best approach to keep AML from returning in older patients, potentially improving long-term survival without the need for indefinite medication.
- What could go wrong
- This is a phase II trial with a relatively small number of participants, so results may not apply to all patients. Stem cell transplants carry serious risks, including infection and graft-versus-host disease, and the drug combination may cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, 07645, United States
Contact Email: •••••@•••••
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Contact Email: •••••@•••••
-
Memorial Sloan Kettering Cancer Center - Suffolk (Limited Protocol Activities)
Commack, New York, 11725, United States
Contact Email: •••••@•••••
-
Memorial Sloan Kettering Monmouth (Consent and Follow-up)
Middletown, New Jersey, 07748, United States
Contact Email: •••••@•••••
-
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, 07748, United States
Contact Email: •••••@•••••
-
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, 10604, United States
Contact Email: •••••@•••••
-
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a targeted drug plus donor immune cells fight back against relapsed leukemia?
- Can a Two-Drug combo outsmart a deadly leukemia?
- Can a new pill take on Hard-to-Treat leukemia?
- Leukemia drug cocktail aims to boost remission in High-Risk patients
- Could bone marrow from deceased donors cure blood cancers?